Navigation Links
Roche Launches EMR Interface for VA to Facilitate Diabetes Management
Date:4/18/2011

INDIANAPOLIS, April 18, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has introduced a new Electronic Medical Record (EMR) interface for the U.S. Department of Veterans Affairs (VA) that helps VA healthcare facilities improve their efficiency and accuracy by transmitting patient diabetes management data directly into the VistA computerized patient record system (CPRS).

The new JResultNet™ middleware module from Dawning Technologies Inc. enables VA providers to transfer patient blood glucose test results automatically and securely to their EMR from the ACCU-CHEK® 360 Diabetes Management System, a tool designed to help physicians and patients manage diabetes in an outpatient setting. Dawning is a leading supplier of connectivity solutions to the clinical laboratory market.

"This integration package allows any provider within the VA's healthcare system to access a patient's glucose test results, and it offers them a much easier, more accurate way to capture the information and deliver it to the patient's EMR," said Keith Snyder, director of marketing at Roche Diagnostics Corporation. "It has already been successfully implemented at several VA sites, and is contributing to improved efficiency levels."

The JResultNet middleware module delivers test results from the ACCU-CHEK 360 system to the VistA system as an HL7-based TIU (text integration utility) connection – a standard component of the VistA system. The enhanced connectivity helps reduce the potential for errors and helps increase workflow efficiency for the healthcare provider.

About Diabetes and the VADiabetes impacts over 20 percent of VA patients, representing more than 1 million veterans at any given time, and that number continues to rise. The cost of treating complications from diabetes is significant, with one diabetes-related heart attack estimated to cost over $14,000.  The VA's diabetes programs are focused on reducing preventable morbidity and mortality.  Providing secure, automated access to patient glucose results for the entire healthcare team can help facilitate the achievement of that goal.

About Dawning Technologies Inc.Dawning Technologies Inc. is a leading supplier of connectivity solutions to the clinical laboratory market. In business since 1984, Dawning solutions are installed in over 4,000 client sites worldwide. Their customers include information system vendors, IVD instrument manufacturers, POC system vendors and clinical laboratories of all forms. Dawning solutions are available for nearly all clinical analyzers, POC and system-to-system connections. For more information contact their web site at www.dawning.com.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

ACCU-CHEK is a trademark of Roche. Please note that a degree symbol follows the name ACCU-CHEK 360 but is not included due to limitations of website symbol translation capabilities. JResultNet is a trademark of Dawning Technologies. All trademarks used or mentioned in this release are protected by law.For further information, please contact: Betsy CoxDirector, Corporate CommunicationsRoche Diagnostics CorporationIndianapolis, IN(317) 521-3911betsy.cox@roche.com
'/>"/>

SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Completes Acquisition of Laprolan
2. MITs Koch Institute to use Roche LightCycler 480 System to Help Advance Cancer Research
3. Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
4. Janet Hammond Joins Roche as Vice President, Translational Medicine - Virology
5. Cellular Dynamics International and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
6. Roche Teams with Womack Army Medical Center to Become First IVD Manufacturer approved for Remote Network Connectivity with DOD
7. Rochester Medical Reports First Quarter Results and Recent Developments
8. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
9. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
10. Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients
11. Rochester Medical Reports Fourth Quarter and Year-End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... , July 13, 2017 It should come ... States is in the midst of a crippling ... , since 1999, the number of overdose deaths from opiate-based ... in over half a million dead from 2001 to 2015". ... oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling link ...
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful ... Carpal tunnel syndrome affects more than 8 million people a year. ... men. The common methods of treating CTS are painful surgery, the ... or gloves. ... CarpalAID is a clear patch worn on the palm of ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 19, 2017 , ... A July ... lead to, or worsen, varicose veins in some patients, according to medical experts. ... certain not-so-good practices, like excessive sitting or standing, or regularly nicking yourself while ...
(Date:7/20/2017)... ... July 20, 2017 , ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s ... Bieniek. Edward Steven Bieniek Jr. was born in Toledo, Ohio. He attended Woodward ... tech. He is married to a brilliant woman with a caring heart named Tiina, ...
(Date:7/18/2017)... ... July 18, 2017 , ... Cognition Corporation , ... two more sessions of its “From the Helm” Webinar Series. , These ... David Cronin, Cognition’s CEO, the half-hour public webinars will take an in-depth look ...
(Date:7/18/2017)... ... ... of an international clinical trial, led in part by a UC Davis School of Medicine ... promise for a subgroup of patients. , In a paper just published online in the ... in 18 countries describe the clinical benefit of using the drug ataluren for a certain ...
(Date:7/18/2017)... ... July 18, 2017 , ... An inventor from Anacortes, ... "Due to menopause, I have frequent hot flashes, and I suffer from anxiety and ... way to keep cool while out and about." INSTA-FAN meets that need. , This ...
Breaking Medicine News(10 mins):